Division of GlaxoSmithKline PLC
Latest From ViiV Healthcare
Analysts are waiting to see how the drugs giant intends to drive growth for new products, with a particular interest in the prospects for the PARP inhibitor Zejula and the single-pill, two-drug HIV therapy Dovato.
The World Health Organization has published its latest list of essential medicines, with a number of expensive drugs for cancers and autoimmune disorders figuring for the first time. The organization says that all patients should have access to life-saving medicines regardless of their ability to pay, but the pharmaceutical industry says this should be done with caution to avoid undermining innovation.
Top-line results from the Phase III TANGO study suggests that switching to ViiV’s two-drug Dovato from a three-drug regimen does not affect the efficacy of treatment.
The approval of ViiV’s new once-daily, two-drug single-pill for HIV/AIDS could lead to a tough battle in Europe with established therapies.
- Therapeutic Areas
- Infectious & Viral Diseases
- GSK Pfizer HIV
- Western Europe
- Parent & Subsidiaries
- GlaxoSmithKline PLC
- Senior Management
Jerome Andries, CFO
John Pottage, MD, CSO & CMO
Gregory Reinaud, Head, Global Commercial Strategy
- Contact Info
Phone: (44) (0)20 8380 6200
980 Great West Rd.
Brentford, TW8 9GS
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.